We protect your health through science

Investigation

Arbovirus and imported viral diseases

Research Lines

Content with Areas Convocatorias Internacionales SALUD GLOBAL .

Research projects

Content with Areas Convocatorias Internacionales SALUD GLOBAL .

Publications

Sort
Category

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, Erick de la Torre-Tarazona H, Arribas JR, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group. EClinicalMedicine. 2022; 50:101529

PUBMED DOI

Elite controllers long-term non progressors present improved survival and slower disease progression

Capa L, Ayala-Suárez R, De La Torre Tarazona HE, González-García J, Del Romero J, Alcamí J, Díez-Fuertes F. Sci Rep. 2022; 12(1):16356

PUBMED DOI

Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection

Diez-Fuertes F, López-Huertas MR, García-Pérez J, Calonge E, Bermejo M, Mateos E, Martí P, Muelas N, Vílchez JJ, Coiras M, Alcamí J, Rodríguez-Mora S. Front Cell Dev Biol. 2022; 10:839813

PUBMED DOI

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J; CombiVacS Study Group. Lancet. 2021; 398(10295):121-130

PUBMED DOI

Content with Areas Convocatorias Internacionales SALUD GLOBAL .

Additional Information

Our objectives are research into well-established autochthonous viruses (Toscana, West Nile and Lymphocoriomeningitis), imported viruses with a vector in Spain (mainly Zika, Dengue and Chikungunya), and viruses that cause haemorrhagic fevers (such as Ebola, Lassa or Crimea Congo, which despite being autochthonous, we include in this category) without forgetting other viruses that, at any time, may become emerging viruses and cause public health alerts.

The group's main research objective is to identify and characterise the aforementioned viruses that cause disease and those circulating in our environment with pathogenic potential.

One of the cross-cutting objectives of the laboratory is to optimise methods for the detection of these viruses and their application to determine the incidence, prevalence and/or presence of the viruses in our environment.

However, in addition to methodological development, it is important to know the origin of the circulating viruses, their antigenic relationships with related viruses, the pathogenicity of the different isolates or the interactions of the agents with their host both in cell culture and in arthropod vectors when this is possible. The aim is to strengthen our role as a National Reference Laboratory for zoonoses through research.

Our objectives are research into well-established autochthonous viruses (Toscana, West Nile and Lymphocoriomeningitis), imported viruses with a vector in Spain (mainly Zika, Dengue and Chikungunya), and viruses that cause haemorrhagic fevers (such as Ebola, Lassa or Crimea Congo, which despite being autochthonous, we include in this category) without forgetting other viruses that, at any time, may become emerging viruses and cause public health alerts.

The group's main research objective is to identify and characterise the aforementioned viruses that cause disease and those circulating in our environment with pathogenic potential.

One of the cross-cutting objectives of the laboratory is to optimise methods for the detection of these viruses and their application to determine the incidence, prevalence and/or presence of the viruses in our environment.

However, in addition to methodological development, it is important to know the origin of the circulating viruses, their antigenic relationships with related viruses, the pathogenicity of the different isolates or the interactions of the agents with their host both in cell culture and in arthropod vectors when this is possible. The aim is to strengthen our role as a National Reference Laboratory for zoonoses through research.

Content with Areas Convocatorias Internacionales SALUD GLOBAL .